At a time when the world of medical imaging is all about artificial intelligence, our aim is to bring it within your reach!
Our technology lets radiologists and clinicians focus on quality of care by building artificial intelligence systems into their workflow, all with a focus on clinical needs.
Our natively AI-powered clinical apps are built to the highest clinical standards.
Innovative, collaborative solutions fully integrated into any healthcare information system
20 years
of innovation
1,200 customers
worldwide
70 employees
committed to saving lives
170 scientific papers
and several technology patents
Intrasense news
CE certification for Myrian® 2.14 advanced visualization solution
15 April 2025
Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up, announces that it has obtained CE marking under MDR (Medical Device Regulation) for Myrian® 2.14, the new version of its advanced radiology visualization solution. This new CE marking for Intrasense's innovative solutions […]
Full-year results for 2024 down against a backdrop of transformation, product range expansion and strategic investments to drive tomorrow's growth
26 March 2025
Intrasense (ISIN : FR0011179886), a French expert in medical imaging solutions facilitating diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2024 annual results and its new strategic roadmap. These financial statements were approved on March 25, 2025, by the Board of Directors. The audit procedures on the consolidated accounts have been completed, and the […]
US Food and Drug Administration (FDA) grants Breakthrough Device status to Guerbet innovation: DUOnco Pancreas for early detection of pancreatic lesions
20 March 2025
Guerbet (FR0000032526 GBT), a world leader in medical imaging solutions, today announced that the US Food and Drug Administration (FDA) has granted “Breakthrough Device” designation to DUOncoTM Pancreas for which Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, will be the […]
DUOnco Bone : First CE marked IA algorithm for automatic detection of bone lesions on CT scan
18 March 2025
Montpellier, France, march 18, 2025. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, and Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), announces the CE marking under MDR (Medical Device Regulation) DUOnco™ Bone, an innovate […]
Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.
Presentation of the Liflow® solution at the AI Action Summit event in Paris, as part of AI Action Week
12 February 2025
Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, took part in the Side Event AI Action Summit, an event held on February 11, 2025 at the Grand Palais in Paris, as part of AI Action Week.
Intrasense: 2024 annual sales of €2.2m, against a backdrop of transformation and strategic investment
6 February 2025
Intrasense (ISIN: FR0011179886 - Mnemo: ALINS), a French expert in AI-enhanced medical imaging solutions facilitating and securing diagnosis, decision-making and therapeutic follow-up, publishes its consolidated sales for the full year 2024.
Intrasense presence at ECR (European Congress of Radiology) from February 26 to March 2, 2025 in Vienna
3 February 2025
Montpellier, France, February 3, 2025. Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, announces its participation in the European Congress of Radiology (ECR) 2025, which will take place between February 26 and March 2 in Vienna (Austria).
Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.
Intrasense announces the CE marking of Liflow®’s new version enhanced by AI dedicated to the liver
16 December 2024
Intrasense (FR0011179886 - ALINS), medical imaging software solutions expert and developer of Myrian® et Liflow®, is proud to announce that the Lilfow® solution obtained the CE certification under MDR1, integrating a new AI algorithm for the detection of focal liver lesions developed in collaboration with Guerbet (trade name: DUOnco™ Liver). This new version is being […]
Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow®, innovative solution dedicated to oncology imaging
3 December 2024
Guerbet (FR0000032526 GBT) worldwide expert in contrast agents and medical imaging solutions, Intrasense (FR0011179886 - ALINS), expert in medical imaging software solutions and developer of Myrian® and Liflow®, Gustave Roussy, 1st cancerology centre in France and Europe and Angers University Hospital (« Partners ») announce they have received €5.9M in funding from Bpifrance’s “Innovation in […]
Intrasense announces the CE marking of Myrian 2.13, enriched by the new version of Guerbet’s prostate AI
20 November 2024
Intrasense (FR0011179886 - ALINS), medical imaging software expert and developer of Myrian® and Liflow®, is proud to announce that the Myrian® 2.13 platform has obtained the CE marking under MDR1, including a major new version of the prostate AI developed by Guerbet, Veolity® LungCAD AI developed by MeVis Medical Solutions AG and Icobrain™ AI developed […]
Intrasense announces its participation in RSNA 2024, the world's leading medical imaging congress
6 November 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in the RSNA 2024 international imaging congress. Intrasense will be showcasing its new Liflow® solution, as well as the innovations of the new version of Myrian®, on the stand of its partner Guerbet, symbolizing a collaboration […]
Liflow®, a solution dedicated to oncology imaging, wins the JFR 2024 Innovation Prize in the “Healthcare IT and AI” category
30 September 2024
Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian® and Liflow®, is proud to announce that its Liflow® solution has been awarded the Prix Innovation JFR (Journées Francophones de la Radiologie) 2024 in the “Healthcare IT and AI” category.
Intrasense announces its half-year results for 2024
25 September 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® et Liflow®, announces its consolidated IFRS half-year results for 2024.
Guerbet and Intrasense announce the CE marking of DUOnco™ Liver, an artificial intelligence algorithm designed to detect focal liver lesions
23 September 2024
Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announce the CE marking under MDR of the liver AI developed by Guerbet (trading name: DUOnco™ Liver).
Intrasense attends the « Journées Francophones de Radiologie » 2024
9 September 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® and Liflow® developer, announces its attendance in Journées Francophones de Radiologie (JFR) 2024, where will be presented for the first time the new solution Liflow® as well as the innovations of the new version of Myrian®.
Alexandre Salvador appointed CEO of Intrasense to accelerate strategic repositioning on high value-added medical solutions integrating AI in radiology
27 August 2024
The Board of Directors of Intrasense (FR0011179886 - ALINS), metting on August, 28 2024 at 5:30 pm under the chairmanship of Mr. François NICOLAS, has decided to appoint Mr. Alexandre SALVADOR as Chief Executive Officer of Intrasense.
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow® (the "Company"), today announced its half-year revenue for 2024 IFRS consolidated at Group level.
Intrasense presents its AI innovations at the SIRM congress in Italy
10 June 2024
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in SIRM, the congress organized by the Italian Society of Medical and Interventional Radiology, to be held from June 20 to 23 in Milan (Italy).
